Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
As shown during the 2009 pandemic H1N1 (A(H1N1)pdm09) outbreak, egg-based influenza vaccine production technology is insufficient to meet global demands during an influenza pandemic. Therefore, there is a need to adapt cell culture-derived vaccine technology using suspended cell lines for more rapid and larger-scale vaccine production. In this study, we attempted to generate a high-growth influenza vaccine strain in MDCK cells using an A/ Puerto/8/1934 (H1N1) vaccine seed strain. Following 48 serial passages with four rounds of virus plaque purification in MDCK cells, we were able to select several MDCK-adapted plaques that could grow over 108 PFU/ml. Genetic characterization revealed that these viruses mainly had amino acid substitutions in internal genes and exhibited higher polymerase activities. By using a series of Rg viruses, we demonstrated the essential residues of each gene and identified a set of high-growth strains in MDCK cells (PB1D153N, M1A137T, and NS1N176S). In addition, we confirmed that in the context of the high-growth A/PR/8/34 backbone, A/ California/7/2009 (H1N1), A/Perth/16/2009 (H3N2), and A/environment/Korea/deltaW150/ 2006 (H5N1) also showed significantly enhanced growth properties (more than 107 PFU/ml) in both attached- and suspended-MDCK cells compared with each representative virus and the original PR8 vaccine strain. Taken together, this study demonstrates the feasibility of a cell culture-derived approach to produce seed viruses for influenza vaccines that are cheap and can be grown promptly and vigorously as a substitute for egg-based vaccines. Thus, our results suggest that MDCK cell-based vaccine production is a feasible option for producing large-scale vaccines in case of pandemic outbreaks.
Abstract
As shown during the 2009 pandemic H1N1 (A(H1N1)pdm09) outbreak, egg-based influenza vaccine production technology is insufficient to meet global demands during an influenza pandemic. Therefore, there is a need to adapt cell culture-derived vaccine technology using suspended cell lines for more rapid and larger-scale vaccine production. In this study, we attempted to generate a high-growth influenza vaccine strain in MDCK cells using an A/ Puerto/8/1934 (H1N1) vaccine seed strain. Following 48 serial passages with four rounds of virus plaque purification in MDCK cells, we were able to select several MDCK-adapted plaques that could grow over 108 PFU/ml. Genetic characterization revealed that these viruses mainly had amino acid substitutions in internal genes and exhibited higher polymerase activities. By using a series of Rg viruses, we demonstrated the essential residues of each gene and identified a set of high-growth strains in MDCK cells (PB1D153N, M1A137T, and NS1N176S). In addition, we confirmed that in the context of the high-growth A/PR/8/34 backbone, A/ California/7/2009 (H1N1), A/Perth/16/2009 (H3N2), and A/environment/Korea/deltaW150/ 2006 (H5N1) also showed significantly enhanced growth properties (more than 107 PFU/ml) in both attached- and suspended-MDCK cells compared with each representative virus and the original PR8 vaccine strain. Taken together, this study demonstrates the feasibility of a cell culture-derived approach to produce seed viruses for influenza vaccines that are cheap and can be grown promptly and vigorously as a substitute for egg-based vaccines. Thus, our results suggest that MDCK cell-based vaccine production is a feasible option for producing large-scale vaccines in case of pandemic outbreaks.
참고문헌 (40)
- Garten RJ, "Antigenic and genetic characteristics of swineorigin 2009 A (H1N1) influenza viruses circulating in humans", Science, 325, pp.197~201 (2009)[DOI]
- Saito T, "Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation", J. Med. Virol., 74, pp.336~343 (2004)[DOI]
- Grohskopf LA, "Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP)-United States, 2016-17 influenza season", MMWR Recomm. Rep., 65, pp.1~54 (2016)
- Dawood FS, "Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study", Lancet Infect Dis, 12, pp.687~695 (2012)[DOI]
- Larson RC, "Modeling the effects of H1N1 influenza vaccine distribution in the United States", Value Health, 15, pp.158~166 (2012)[DOI]
- Lee M-S, "A cell-based backup to speed up pandemic influenza vaccine production", Trends Microbiol, 20, pp.103~105 (2012)[DOI]
- Gaush CR, "Replication and plaque assay of influenza virus in an established line of canine kidney cells", J. Appl. Microbiol., 16, pp.588~594 (1968)
- Govorkova E, "Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells", Virology, 262, pp.31~38 (1999)[DOI]
- Audsley JM, "Cell-based influenza vaccines", Drugs, 68, pp.1483~1491 (2008)[DOI]
- Genzel Y, "Continuous cell lines as a production system for influenza vaccines", Expert Rev. Vaccines, 8, pp.1681~1692 (2009)[DOI]
- Ulmer JB, "Vaccine manufacturing: challenges and solutions", Nat. Biotechnol., 24, pp.1377~1383 (2006)[DOI]
- Doroshenko A, "Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines)", Expert Rev. Vaccines, 8, pp.679~688 (2009)[DOI]
- Song JY, "Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): a randomized, double-blind, multi-center, phase 3 clinical trial", Vaccine, 33, pp.5437~5444 (2015)[DOI]
- "Understanding vaccines, vaccine development and production"[URL]
- Shin D, "Comparison of immunogenicity of cell- and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines", Virus Res, 204, pp.40~46 (2015)[DOI]
- Song M-S, "Establishment of Vero cell RN A polymerase I-driven reverse genetics for influenza A virus and its application for pandemic (H1N1) 2009 influenza virus vaccine production", J. Gen. Virol., 94, pp.1230~1235 (2009)
- Song M-S, "The polymerase acidic protein gene of influenza A virus contributes to pathogenicity in a mouse model", J. Virol., 83, pp.12325~12335 (2009)[DOI]
- Lohr V, "A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor", Vaccine, 28, pp.6256~6264 (2010)[DOI]
- Reed LJ, "A simple method of estimating fifty per cent endpoints", Am. J. Epidemiol., 27, pp.493~497 (1938)[DOI]
- Rocha EP, "Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses", J. Gen. Virol., 74, pp.2513~2518 (1993)[DOI]
- Schild G, "Evidence for host-cell selection of influenza virus antigenic variants", Nature, 303, pp.706~709 (1983)[DOI]
- Dumitrescu M, "A three years experience in using MDCK cell line for influenza virus isolation (1979-1981)", Arch. Roum. Pathol. Exp. Microbiol., 40, pp.313~ (1981)
- Gambaryan AS, "Receptor-binding properties of swine influenza viruses isolated and propagated in MDCK cells", Virus Res, 114, pp.15~22 (2005)[DOI]
- Stevens J, "Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs", J. Virol., 84, pp.8287~8299 (2010)[DOI]
- "Novartis receives FDA approval for Flucelvax, the first cell-culture vaccine in US to help protect against seasonal influenza"[URL]
- Tanzi MG, "Flucelvax: first seasonal vaccine using cellculture technology", Pharm. Today, 19, pp.31~ (2013)[DOI]
- Ping J, "Development of high-yield influenza A virus vaccine viruses", Nat. Commun., 2, pp.8148~ (2015)
- Hale BG, "The multifunctional NS1 protein of influenza A viruses", J. Gen. Virol., 89, pp.2359~2376 (2008)[DOI]
- Watanabe T, "NS1 is the fluid for "flu-transmission"", Proc. Natl. Acad. Sci. USA, 114, pp.11012~11014 (2017)[DOI]
- Genzel Y, "Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media", Vaccine, 24, pp.6074~6087 (2006)[DOI]
- Hu AYC, "Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines", Vaccine, 26, pp.5736~5740 (2008)[DOI]
- Merten O, "Production of influenza virus in serum-free mammalian cell cultures", Dev. Biol. Stand., 98, pp.73~94 (1999)
- Tree JA, "Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains", Vaccine, 19, pp.3444~3450 (2001)[DOI]
- Hannoun C, "The evolving history of influenza viruses and influenza vaccines", Expert Rev. Vaccines, 12, pp.1085~1094 (2013)[DOI]
- Keitel W, "Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1", 2 clinical trial, 2010, pp.28, 840~848
- Qiao C, "Vaccines developed for H5 highly pathogenic avian influenza in China", Ann. N.Y. Acad. Sci., 1081, pp.182~192 (2006)[DOI]
- Shi H, "Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses", Vaccine, 25, pp.7379~7384 (2007)[DOI]
- Roy P, "Virus-like particles as a vaccine delivery system: myths and facts", Adv. Exp. Med. Biol., 655, pp.145158~ (2009)
- Murakami S, "Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production", J. Virol., 82, pp.1605~1609 (2008)[DOI]
- Gabriel G, "Differential polymerase activity in avian and mammalian cells determines host range of influenza virus", J. Virol., 81, pp.9601~9604 (2007)[DOI]